Skip to Content

Tritanrix HepB

Active Substance: diphtheria toxoid / hepatitis B recombinant surface antigen / Bordetella pertussis (inactivated) / tetanus toxoid
Common Name: diphtheria, tetanus, pertussis (whole cell) and hepatitis-B (rDNA) vaccine (adsorbed)
ATC Code: J07CA05
Marketing Authorisation Holder: GlaxoSmithKline Biologicals S.A.
Active Substance: diphtheria toxoid / hepatitis B recombinant surface antigen / Bordetella pertussis (inactivated) / tetanus toxoid
Status: Withdrawn
Authorisation Date: 1996-07-19
Therapeutic Area: Hepatitis B Diphtheria Whooping Cough Immunization Tetanus
Pharmacotherapeutic Group: Vaccines

Therapeutic Indication

Tritanrix HepB is indicated for active immunisation against diphtheria, tetanus, pertussis and hepatitis B (HBV) in infants from six weeks onwards (see section 4.2).

The marketing authorisation for Tritanrix HepB has lapsed because it ceased to be marketed in the European Union more than three years ago and an exemption granted by the European Commission has expired

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide